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Gene transfer into stimulated and unstimulated T
lymphocytes by HIV-1-derived lentiviral vectors
E Costello, M Munoz, E Buetti, PRA Meylan, H Diggelmann and M Thali
Institute of Microbiology, University of Lausanne, Switzerland
Genetic modification of T lymphocytes holds great potential
for treatments of cancer, T cell disorders and AIDS. While
in the past recombinant murine retroviruses were the vectors
of choice for gene delivery to T cells, vectors based on lenti-
viruses can provide additional benefits. Here, we show that
VSV-G pseudotyped HIV 1 vector particles delivering the
enhanced green fluorescent protein (EGFP) efficiently trans-
duce human T lymphocytes. Transduction efficiency was
optimal when infection included centrifugation of cells with
concentrated vector supernatant in the presence of
Polybrene. In contrast to previous reports describing murine
retrovirus-mediated gene transfer to T lymphocytes, fib-
ronectin did not improve the transduction efficiency of the
VSVG-pseudotyped HIV-1 particles. Similar gene transfer
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Introduction
Genetic modification of T lymphocytes offers potential
correction or treatment of diseases, including certain
inherited disorders, eg adenosine deaminase deficiency;
and acquired diseases, eg acquired immune deficiency
syndrome (AIDS) and cancer. To date the most widely
investigated method for gene transfer to human T cells
has involved murine retroviral vectors.1–3 These vectors
are appealing as tools for gene therapy because they have
a relatively large cloning capacity, do not transfer viral
genes and the transferred therapeutic gene is stably inte-
grated into the chromosome of the host cell. However,
efficient infection depends on expression by the target
cell, of the receptor for the amphotropic retroviral envel-
ope. This potential obstacle can be overcome by the use
of alternative viral envelopes that target distinct receptors
on the target cell, eg the gibbon ape leukemia virus
(GALV) envelope or the G protein of vesicular stomatitis
virus (VSV). An additional drawback of murine retroviral
vectors is the inability to transduce cells which do not
undergo division following infection. Retroviral vectors
based on lentiviruses do not have this limitation. These
vectors may be a useful alternative for gene therapy of
human T cells.
Retroviruses belong to a family of RNA viruses whose
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efficiencies were observed following stimulation of cells with
PHA/IL-2 or anti-CD3i/CD28i antibodies, although greater
transgene expression was observed in the latter case. Inter-
estingly, production of vectors in the absence of the access-
ory proteins Vif, Vpr, Vpu and Nef was accompanied by a
50% decrease in transduction efficiency in activated T cells.
Transduction of T cells that were not stimulated before infec-
tion was achieved. No transduction of non-prestimulated
cells was observed with a GALV-pseudotyped murine retro-
viral vector. The requirement for accessory proteins in non-
prestimulated cells was more pronounced. Our results have
implications for lentiviral vector targeting of other cells of the
hematopoietic system including stem cells. Gene Therapy
(2000) 7, 596–604.
replication involves the production of a DNA intermedi-
ate. The simpler retroviral genomes have three genes, gag,
pol and env. The more complex lentiviruses, as well as
encoding Gag, Pol and Env, also encode several regulat-
ory and accessory proteins. HIV-1, for example, encodes
the regulatory proteins Rev and Tat and the accessory
proteins Vif, Vpr, Vpu and Nef. Vectors based on HIV-1
have been described.4 Most are produced by co-
transfection of three plasmid constructs: (1) a packaging
construct containing all the HIV-1 genes except env; (2)
an expression plasmid for the G protein of VSV; and (3)
a transfer vector containing a promoter-driven gene of
interest. These vectors have been shown to infect a wide
range of different cell types in vitro and in vivo. Notably,
transduction of non-dividing cells has been demon-
strated, including growth arrested fibroblasts and differ-
entiated macrophages in culture and neuronal cells,
hepatocytes, and myocytes in vivo.5–8
A primary concern over the use of lentiviral vectors
is their biosafety. Several modifications to the producer
system described above have been made to avoid toxicity
and reduce the possibility of producing replication-
competent HIV-1. Viral accessory genes, which are asso-
ciated with virulence, have been eliminated from the vec-
tor genome,9,10 genes on the packaging plasmid have
been further separated on to two plasmids11 and pro-
duction of self-inactivating vectors has been described.12
Rev independent vector systems have also been
proposed.8,13 More recently, a vector system which
packages an HIV-1 transfer cassette into a simian
immunodeficiency virus particle has been developed.14
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anti-HIV genes. The HIV long terminal repeat (LTR) and
the Rev responsive element (RRE) present on the transfer
vector RNA genome may compete with those of a HIV-
1 viral genome, effectively acting as decoys for Tat and
Rev activity, thus impairing viral replication.15 In
addition, vector RNA may compete with genomic RNA
for packaging and thus be mobilised to other target cells.
Human CD4+ T lymphocytes are a natural host for infec-
tion by HIV-1. Non-pseudotyped HIV-1-derived vectors
have been shown to transduce CD4+ T cell lines.16–18 Mat-
suoka et al19 demonstrated transduction of human pri-
mary T cells with non-pseudotyped HIV-1-based vectors
but the apparent efficiency of transduction was extremely
low. In this study, we show that (1) VSVG-pseudotyped
lentiviral vectors efficiently transduce primary T lympho-
cytes, and we describe adaptations to the transduction
protocol that resulted in high levels of gene transfer. (2)
The lentiviral vectors are able to transduce freshly iso-
lated T cells in the absence of any prestimulation,
whereas a murine retroviral vector was unable to do so
under the same conditions. (3) HIV accessory proteins are
required for maximal transduction of T cells, particularly
when the cells were unstimulated before infection.
Results
Optimisation of VSVG-pseudotyped lentiviral vector-
mediated gene transfer to T-lymphocytes
Modifications, in recent years, to protocols for retrovirus-
mediated gene delivery to T lymphocytes have resulted
in improved gene transfer efficiencies. Such modifi-
cations include incubation of vector supernatant and tar-
get cells in the presence of polycations such as Polybrene,
co-centrifugation of vector and cells20 and co-localisation
of retrovirus and target cells on the extracellular matrix
molecule fibronectin.21–23 We first examined whether
using VSVG-pseudotyped lentiviral vectors, we could
accomplish the same levels of gene transfer that are cur-
rently achieved with optimised protocols for murine
retrovirus-mediated gene transfer to T cells. To generate
infectious HIV-1 based vectors containing all accessory
proteins, a packaging plasmid PCWT (see Materials and
methods, Figure 1a), a transfer vector containing the
EGFP gene under the control of the murine pgk promoter
(see Materials and methods, Figure 1b), and a plasmid
expressing the VSVG protein from a CMV promoter
(pMD.G5, Figure 1c) were co-transfected into 293T cells.
Following concentration, vectors with a titer (on HeLa
cells) in excess of 1 · 107 were obtained. T cells were acti-
vated, following isolation of PBMCs, for 48 h with
PHA/IL-2. This treatment led to a cell population, 90%
of which were T cells, as assessed by anti-CD3 staining
and FACS analysis (data not shown). The cells were
transduced at a nominal (based on HeLa cells) MOI of
0.6. This resulted in transduction of approximately 4% of
the cells (Figure 2a), indicating that the effective MOI of
T cells, calculated using the Poisson distribution, was
approximately 0.04. Incubation of the vector supernatant
and cells in the presence of 5 mg/ml Polybrene (higher
concentrations of Polybrene were toxic to T cells, data not
shown) resulted in an approximate two-fold increase in
the percentage of cells transduced. Centrifugation of
vector supernatant and cells during infection was
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accompanied by a five-fold increase in transduction
efficiency. The combination of both Polybrene and centri-
fugation resulted in a slightly higher percentage of cells
transduced (six-fold increase over control). Thus, both
Polybrene and centrifugation enhanced transduction
efficiency although the fold-enhancement seen with
centrifugation was higher than that measured with
Polybrene.
Several reports have shown that transduction of T lym-
phocytes on human fibronectin improved efficiency of
retrovirus gene transfer.21,23 PBMCs were stimulated with
immobilized antibodies to CD3 and CD28 (CD3i/CD28i),
a treatment which results in the selective growth of T
cells. We measured the percentage of EGFP positive cells
following transduction on plates coated with BSA or
recombinant fibronectin fragments (Figure 2b). Only a
modest increase in transduction was found when fib-
ronectin was used. This small increase (approximately
1.1-fold) in transduction efficiency with fibronectin was
consistently observed in multiple experiments (n = 7) and
depended neither on the MOI nor on the mode of stimu-
lation. In contrast, fibronectin-mediated transfer was sig-
nificantly enhanced using a GALV-pseudotyped murine
retroviral vector (data not shown), demonstrating that
the effect of fibronectin depends upon the nature of the
pseudotyped envelope.
Nevertheless, upon optimisation of the lentivirus pro-
tocol by including a centrifugation step with Polybrene,
and a (nominal) MOI in excess of two, transduction
efficiencies of 30% or greater were obtained. Figure 2c
shows the result of lentiviral vector infection of stimu-
lated T cells from three independent donors. Transduc-
tion efficiencies ranged from 35 to 46%, with a mean of
40%. It should be noted that in general, the levels of
EGFP positive cells observed on day 3 after transduction
were 1.5- to 1.9-fold higher than those observed on day
5 after transduction. From day 5 onwards, the percentage
of EGFP+ cells remained relatively stable for 14 days after
transduction. Thus, the initial high level of transduction
measured, likely reflects pseudo-transduction or transient
expression from non-integrated vector DNA.24
To determine whether both CD4+ and CD8+ T lympho-
cytes were transduced, EGFP fluorescence and CD4 or
CD8 expression were monitored concurrently. Equivalent
percentages of CD4+ and CD8+ cells were found to be
positive for EGFP (Figure 2d) indicating that both
populations are equal targets for transduction by the
lentiviral vector.
Effect of T cell activation on VSVG-pseudotyped
lentivirus-mediated gene transfer
Human peripheral blood lymphocytes are predominantly
in a resting state but can be activated in vitro by a variety
of methods. Protocols for murine retrovirus-mediated
gene transfer included a T cell activation step to induce
cells to divide. The manner in which T lymphocytes are
activated has been shown to affect efficiency of transduc-
tion by retroviral vectors.21,23,25 We compared the levels
of transduction observed with lentiviral vectors following
stimulation of PBMCs for 48 h with CD3i/CD28i or with
PHA and IL-2. On day 5 after transduction a similar per-
centage of EGFP positive cells was observed with both
methods of stimulation (Figure 3a), although we consist-
ently found that the efficiency of transduction was donor-
dependent. Interestingly, while the percentage of cells
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Figure 1 Schematic representation of (a) the packaging construct, (b) transfer vectors and (c) the envelope expression vector.5
Figure 2 Optimisation of VSVG-pseudotyped lentiviral vector-mediated transduction of T lymphocytes. (a) T lymphocytes, stimulated for 48 h with
PHA/IL-2 were transduced with the PCWT vector (MOI = 0.6) for 3 h in tubes in the absence/presence of Polybrene (5 mg/ml) or with/without centrifug-
ation as indicated. Following transduction, cells were processed as described in Materials and methods and EGFP expression measured 5 days later. (b)
PBMCs were stimulated for 48 h with CD3i/28i and subsequently transduced by incubation for 4 h in 100 ml of PCWT supernatant on BSA-coated
plates or on CH-296 (fibronectin)-coated plates. Following transduction, cells were washed, expanded in medium containing IL-2 and analysed for EGFP
expression 5 days later. The results are representative of seven independent experiments. (c) PBMCs from three independent donors (I to III) were
stimulated for 48 h with PHA/IL-2 and subsequently transduced by centrifugation of 1 · 106 cells with 50 ml of a PCWT supernatant (MOI = 2.5) in
the presence of Polybrene as above. Following transduction, cells were washed, expanded as before and analysed for EGFP expression 5 days later. (d)
The phenotype of the transduced cells was assessed by monitoring both EGFP fluorescence and CD4 or CD8 expression. Percentages of cells are indicated
in each quadrant. Similar results were obtained in three independent experiments.
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Figure 3 Effect of T cells stimulation on the efficiency of lentivirus trans-
duction. PBMCs from two donors (I and II) were stimulated for 48 h with
CD3i/CD28i or with PHA/IL-2 and subsequently transduced, in dupli-
cate, as follows: 5 · 106 cells were centrifuged at 22 ° C, 1500 g for 3 h
with 50 ml of PCWT vector supernatant (MOI = 1.6) in the presence of
Polybrene. Following transduction, cells were washed and expanded in
medium containing IL-2 (50 U/ml). EGFP expression was assessed 5 days
later. The percentage of EGFP expressing cells for each duplicate is shown
(a). The mean fluorescence intensity (MFI) of each duplicate transduction
is plotted (b).
transduced was similar following either method of stimu-
lation, the level of EGFP expression, as assessed by mean
fluorescence intensity (MFI), was two-fold greater in
CD3i/CD28i stimulated cells (Figure 3b). However, in the
absence of continuous CD3i/CD28i stimulation this dif-
ference was not maintained. At 11 and 14 days after
transduction, EGFP expression in CD3i/CD28i-
stimulated cells decreased to that observed in PHA/IL-
2-stimulated cells (MFI approximately 50).
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Higher transduction efficiencies were obtained by
vectors produced in the presence of the accessory
proteins of HIV-1
The biosafety of lentiviral vectors derived from HIV-1 is
a legitimate concern. Although the risk of insertional
mutagenesis is the same as for retroviral vectors, the pro-
teins encoded by HIV accessory genes may have toxic or
otherwise harmful effects in the target cells. However,
they may also play a positive role in the transduction pro-
cess. The requirement for lentiviral accessory proteins to
establish efficient transduction is cell type dependent.7,8,10
We examined whether vectors produced in the absence
of Vif and Vpr, Vpu and Nef would transduce activated
T lymphocytes as efficiently as those produced in the
presence of these accessory proteins. The vectors used for
these experiments were produced by co-transfection of
the pgk-EGFP transfer vector and the VSVG expression
plasmid (pMD.G) into 293T cells together with either
pCMVDR8.2 or pCMVDR8.9 packaging plasmids.
pCMVDR8.2 encodes all HIV-1 proteins except Env while
pCMVDR8.9 does not encode Env, Vif, Vpr Vpu or Nef.10
Viral supernatants with equivalent MOIs, as determined
on Hela cells, were then used to infect T lymphocytes
which had been pre-stimulated for 48 h. Transduction
efficiencies ranging from 30% to 36% (mean 32.7%) were
observed in three donors with vector produced from the
packaging construct containing all the HIV-1 accessory
genes (Table 1). Interestingly, infection with vector pro-
duced in the absence of the HIV-1 accessory genes
resulted in a two-fold decrease in transduction efficiency:
the percentage of transduced cells ranged from 14.9 to
17.1, with a mean of 16.2. Thus, although HIV accessory
proteins are not strictly required for T lymphocyte
transduction, their presence enhances this process.
Transduction of non-stimulated T cells
One reason for developing lentiviral vectors is the ability
of lentiviruses to infect non-cycling cells, in contrast to
murine retroviruses, which need host-cell-DNA repli-
cation for infection. We therefore attempted to transduce
Table 1 Higher transduction efficiencies are obtained by vectors
produced in the presence of the accessory proteins of HIV-1
Donor Vector Percentage (%) of EGFP+ cells
Experiment 1 Experiment 2
I (MOI = 2.1) pCMVDR8.2 34.9 31.3
I (MOI = 2.1) pCMVDR8.9 16.8 16.2
I MLV (GALV env) 16.6 19.9
II (MOI = 3.7) pCMVDR8.2 36.0 31.9
II (MOI = 3.8) pCMVDR8.9 16.4 17.1
III (MOI = 3.1) pCMVDR8.2 29.5 ND
III (MOI = 3.3) pCMVDR8.9 14.9 ND
Activated T cells were transduced by centrifugation with Polybrene
using vectors prepared in the presence (pCMVDR8.2) or in the
absence of the HIV-1 accessory proteins Vif, Vpr, Vpu and Nef
(pCMVDR8.9) or with a GALV pseudotyped MLV vector. Follow-
ing transduction, cells were processed as described in Materials and
methods and EGFP expression measured 5 days later. Three inde-
pendent donors were used and the MOI (as determined on HeLa
cells) in each lentivirus experiment is indicated.
ND = not determined.
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freshly isolated T cells, of which greater than 99% are in
the G0/G1 phase of the cell cycle. PBMCs were infected
either immediately following isolation (and therefore
contain a mix of cells, including T cells, B cells and mono-
cytes; donor IV and V, Table 2) or following enrichment
for CD4+ T cells by immunomagneting sorting (donor III,
Table 2; 80% of these cells were CD3+ at the time of trans-
duction, as assessed by anti-human CD3 antibody label-
ling and FACS analysis, not shown). The efficiency of
transduction was measured 5 days after infection.
Measurement at 5 days after infection, and not before,
was carried out to avoid the appearance of false positives
(pseudo-transduction or transient expression from non-
integrated vector DNA). To maintain T cell viability dur-
ing this time, they were stimulated. Thus, following
transduction, cells were stimulated for 48 h with
PHA/IL-2 and maintained in IL-2 containing medium
until the time of harvest. This process also serves to gre-
atly enrich for T cells (Materials and methods), hence,
analysis was carried out on T cells and not on a mixed
population. Significant levels of transduction were achi-
eved with lentiviral vectors. A GALV-pseudotyped MLV-
based vector, as expected, was unable to transduce these
non-pre-stimulated T cells (Table 2, compare pCMVDR8.2
with MLV (GALV env)). An equivalent innoculum of this
MLV-based vector led to transduction of a significant
portion of prestimulated T cells (Table 1). Failure to
detect EGFP expressing cells following infection with the
GALV-pseudotyped MLV vector could be explained if
EGFP was poorly expressed from the Mo-MuLV LTR
compared with the pgk promoter in the lentiviral vector
system. To examine this possibility, we compared the
level of EGFP expression (MFI) following infection of
pre-stimulated T cells with lentiviral vectors and MLV-
based vectors (Figure 4). The MFI following infection of
two independent donors with the lentiviral vector was
between 40 and 55 (Figure 4a). This value corresponds
with the MFI values measured in other experiments
using this vector. Infection with the GALV envelope
Table 2 Transduction of non-stimulated T cells
Donor Vector Percentage of EGFP+
cells
III (MOI = 3.1) pCMVDR8.2 18.3
III (MOI = 3.3) pCMVDR8.9 5.2
III MLV (GALV env) 0.0
IV (MOI = 1.5) pCMVDR8.2 8.0
IV (MOI = 1.6) pCMVDR8.9 2.3
IV MLV (GALV env) 0.0
V (MOI = 1.8) pCMVDR8.2 11.0
V (MOI = 1.8) pCMVDR8.9 6.6
V MLV (GALV env) 0.0
Freshly isolated PBMCs were transduced by centrifugation with
Polybrene using vectors prepared in the presence (pCMVDR8.2) or
in the absence of the accessory proteins HIV-1 Vif, Vpr, Vpu and
Nef (pCMVDR8.9) or with a GALV pseudotyped MLV vector.
Immediately following transduction, cells were plated in medium
containing PHA/IL-2 for 48 h and subsequently in medium con-
taining IL-2 only. EGFP expression was measured at day 5 after
transduction. Three independent donors were used and the MOI
(as determined on HeLa cells) in each lentivirus experiment is
indicated.
pseudotyped murine retrovirus gave rise to a wider
range of EGFP expression. The MFI was approximately
20 times higher (Figure 4b) than that measured with the
pgk-EGFP vectors. It is thus likely that if transduction of
resting T cells with the MLV vector had occurred, we
would have detected it.
Transduction of non-prestimulated T cells with the
pCMVDR8.9 vector showed an increased dependence on
HIV accessory proteins compared with prestimulated
cells. Whereas vectors devoid of accessory proteins were
two-fold less efficient in transducing stimulated cells,
their ability to transduce non-stimulated cells was
decreased by 3.5-fold in some experiments. These data
demonstrate the advantage of lentiviral vectors for the
infection of non-cycling T cells and suggest a role for HIV
accessory genes in the packaging component.
Discussion
We show that VSV-G pseudotyped retroviral vectors
based on HIV-1 can efficiently mediate gene transfer to
human T lymphocytes. In the past, attention has focused
on using onco-retroviral vectors to transduce T cells.
Recent improvements to transduction protocols have
increased the efficiency of gene transfer. We show here
that some, but not all, of these developments can be
adapted to VSVG-pseudotyped lentivirus-mediated gene
transfer to T lymphocytes. A two-fold enhancement in T
cell transduction efficiency was observed when Polyb-
rene was incubated with T cells and lentiviral vector at
the time of infection. Use of the less toxic polycation, pro-
tamine sulphate, may allow higher concentrations to be
used and in turn may result in higher transduction
efficiencies. Of greater significance was the five-fold
enhancement observed following centrifugation of cells
and virus. The combination of centrifugation and Polyb-
rene resulted in a slightly higher overall enhancement of
transduction efficiency. Consequently, transduction was
achieved with low titres of vector (all of the experiments
were carried out with MOIs, as determined on HeLa cells,
less than or equal to 3.3). These modifications to the
transduction protocol may have applications for gene
delivery to other hematopoietic cell types including stem
cells. Miyoshi et al26 detected GFP expression in approxi-
mately 35 and 54% of CD34+ cells following transduction
with a VSVG-pseudotyped lentiviral vector using MOIs
of 60 and 300, respectively. Case et al24 using similarly
high MOIs detected GFP expression in approximately
24% of CD34+ cells. Inclusion of a centrifugation step in
these transduction protocols may result in higher trans-
duction efficiencies or, equally importantly, may allow
the use of less transducing virus.
Pollok et al21 reported that gene transfer to T-lympho-
cytes was three- to nine-fold more efficient when super-
natant infection was carried out on a recombinant frag-
ment (CH-296) of fibronectin, compared with BSA with
Polybrene. Dardalhon et al23 also showed efficient murine
retrovirus-mediated gene transfer to human T cells when
infection was carried out on fibronectin. Interestingly, we
found no significant enhancement in VSVG-pseudotyped
lentiviral vector-mediated gene transfer to T lymphocytes
in the presence of fibronectin. This likely reflects a lack
of binding of the VSV glycoprotein to fibronectin and a
consequent lack of co-localisation of retroviral particles
and cells. This finding highlights an important distinction
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Figure 4 PBMCs from two donors (I and II) were stimulated for 48 h with PHA/IL-2 and subsequently transduced, by centrifugation at 22° C, 1500 g
for 3 h in the presence of Polybrene, with lentiviral vector supernatant (a) or with supernatant containing GALV pseudotyped MLV vector (b). EGFP
fluorescence was monitored by FACS and the percentage of EGFP+ cells and the MFI values for each transduction are shown.
between the commonly used murine retroviruses and
VSVG-pseudotyped lentiviral vectors and should be
taken into consideration when these vectors are being
examined as gene transfer tools to other hematopoietic
cells. Many of the protocols describing efficient murine
retrovirus-mediated gene transfer to T cells involve
transduction of cells on 2 to 3 consecutive days.21,23,27 Our
protocol achieves efficient transduction with a single
infection cycle, providing an advantage for clinical appli-
cations. Recently, Douglas et al28 demonstrated efficient
transduction of activated T lymphocytes using a Tat-
dependent lentivirus-based vector. Thus, the transfer vec-
tor contained a HIV LTR-promoter driven tat gene as
well as a GFP reporter gene. The expression of Tat in
target cells curtails the use of this vector for clinical trials
of human gene therapy.
Several reports using murine retroviral vectors have
indicated that the way in which T cells are activated
influences transduction efficiency. Pollok et al21 activated
T cells in several ways including exposure to interleukin-
2 (IL-2), soluble anti-CD3 monoclonal antibody (CD3s),
immobilised anti-CD3 monoclonal antibody (CD3i), or
co-immobilised CD3 and CD28 monoclonal antibodies
(CD3i/CD28i). They observed highest fibronectin-
mediated transduction efficiencies following activation
with CD3i/CD28i. Similarly, Yang et al25 found that acti-
vation of T lymphocytes by bead-conjugated anti-CD3
and anti-CD28 antibodies resulted in higher levels of
transduction by MLV based vectors than activation by
other means, eg CD3i and recombinant IL-2 or phy-
tohemagglutinin (PHA) and IL-2. Dardalhon et al23
reported that peripheral blood lymphocytes, stimulated
for 2 days with either PHA or immobilised antibodies
(anti-CD3 and anti-CD28) did not significantly alter the
level of fibronectin-mediated murine retroviral gene
transfer (transduction efficiencies ranged from 15 to 45%).
We observed that similar percentages of cells were tar-
geted with VSVG-pseudotyped lentiviral vectors when
cells were pre-stimulated with CD3i/CD28i or PHA/IL-
2, however the level of gene expression was approxi-
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mately two-fold higher in the CD3i/CD28i stimulated
cells. This may reflect an overall higher activation status
achieved with CD3i/CD28i than with PHA/IL-2. Quinn
et al27 studied the relationship between T cell activation
and proviral gene expression. Under conditions where
cells were most highly activated and producing highest
levels of cytokines (IFN-g, TNF-a, IL-4), proviral protein
expression was also highest. Pollok et al21 observed that
fibronectin-facilitated murine retroviral gene transfer to
T cells was more successful following activation of cells
with CD3i/CD28i than with CD3i, CD3s or IL-2 alone. In
our experiments, following transduction, cells were
maintained in IL-2 containing medium. The initial differ-
ence in EGFP expression between CD3i/CD28i and
PHA/IL-2 stimulated cells was not sustained following
2 weeks of culture. This apparent down-regulation of
proviral gene expression in the absence of T cell signal-
ling has been reported by Quinn et al27 and by Pollok et
al.21 In both these studies, reactivation of transduced T
cells was accompanied by re-initiation of proviral gene
expression.
HIV-based vectors devoid of one or more accessory
genes/proteins have been developed, with the aim of
improving their biosafety. Such vectors retained the
ability to transduce non-dividing 293T cells,9,10 growth
arrested HeLa cells,8 differentiated macrophages and
contact-inhibited primary human skin fibroblasts in
vitro,8,10 as well as neuronal cells, hepatocytes and myo-
cytes in vivo.7,10 In some instances, eg transduction of rat
neurons in vivo, no reduction in gene transfer was
observed with vectors produced in the absence of access-
ory proteins. However, in other cases, the efficiency of
transduction was diminished. Vector particles produced
in the absence of Vpr showed a 50% decreased transduc-
tion efficiency in differentiated macrophages in culture.10
Vif/Vpr deleted vectors displayed diminished transduc-
tion efficiency in rodent liver in vivo,7 while Gasmi et al8
described a three-fold reduction in infectivity of access-
ory protein (Vif, Vpr, Vpu and Nef)-deficient vector in
contact-inhibited human primary skin fibroblasts. We
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report here a two-fold reduction in gene transfer to acti-
vated T lymphocytes with vectors produced in the
absence of Vif, Vpr, Vpu and Nef compared with trans-
duction with vectors produced in the presence of these
proteins. Deleted vectors were even less efficient at trans-
ducing cells that had not previously been activated. In
these cells we observed a difference in efficiency of up to
3.5-fold. The reasons why accessory proteins are dispens-
able for efficient transduction of some cell types and not
others are not entirely known. Human T lymphocytes are
a natural host for HIV and it is likely that the virus has
become adapted for replication in these cells. It is, there-
fore, not surprising that the presence of accessory pro-
teins increases transduction efficiency. Vif, a late HIV-1
gene product, has been reported to be essential for the
establishment of productive HIV-1 infection in peripheral
blood T lymphocytes.29 While productive infection is not
a feature of lentiviral vectors, it is possible that a neces-
sary viral function associated with gene delivery, eg
reverse transcription, is less efficient following infection
with virions produced in the absence of Vif. This access-
ory protein has been shown to increase the infectivity of
progeny virions in a producer cell-dependent manner.30
Vif-deficient virions are defective with respect to the
capacity of the HIV-1 reverse transcription complex to
elongate viral DNA efficiently. The result is an inability
to produce full-length viral DNA genomes.31
The largest of the accessory proteins, Nef, is associated
with enhanced infectivity in primary T cells. The differ-
ence in infectivity between Nef+ and Nef- virions is more
pronounced following infection of freshly isolated T cells
which are stimulated after infection than it is following
infection of T cells which are activated before infection.32
Consistent with this, we observed a greater decrease in
transduction efficiency with deleted vectors in freshly
isolated T cells compared with cells that were pre-stimu-
lated. Hence, the absence of Nef may play a role in the
decreased transduction efficiency we observed with
deleted vectors in T lymphocytes. Vpr, a late HIV-1 gene
product, with a role in mediating the nuclear import of
the HIV-1 pre-integration complex has a modest effect on
HIV-1 replication in primary T cells, although its effect
in growth arrested cells such as differentiated macro-
phages is far greater.33 While it is unlikely that the two-
fold decrease in gene transfer to activated T lymphocytes
is due to the lack of Vpr, it may account, in part, for the
larger decrease observed in unstimulated cells. On the
whole, gene transfer with particles produced from pack-
aging constructs harbouring genes for accessory proteins
may be achieved at lower MOIs compensating perhaps
for the increased toxicity. Nevertheless, transduction of T
lymphocytes whether prestimulated or not was observed
with deleted vectors. Given correct conditions, eg trans-
duction with more concentrated vector, efficiencies of
gene transfer compatible with clinical application may
well be achieved.
Quiescent T cells become infected by HIV-1 but the
reverse transcription process does not go to completion,
preventing successful infection. However, application of
a mitogenic signal shortly after infection will allow the
completion of reverse transcription.34 We observed trans-
duction of freshly isolated T cells which had not been
stimulated before infection, and underwent activation
only starting immediately after infection. In contrast to
the results obtained with lentiviral vectors was the lack
of EGFP positive cells following infection of these cells
with a GALV pseudotyped MLV-based vector. For suc-
cessful gene delivery with murine retroviral vectors, cells
must undergo division. However, as was the case for the
lentiviral vectors, PBMCs incubated with the MLV vector
were also stimulated in our experiments immediately
after transduction. Thus, it appears that the lentiviral vec-
tors have an advantage over onco-retroviral vectors for
the transduction of freshly isolated, non-prestimulated T
lymphocytes. The data presented here demonstrate that
VSVG-pseudotyped lentiviral vectors can effectively
mediate gene transfer to T lymphocytes. Thus, they have
enormous potential both as research tools and in a clini-
cal setting to study and treat T cell-associated diseases.
Materials and methods
Plasmid construction
A packaging construct PCWT (Figure 1a), expressing all
the HIV-1 genes except env under the control of the
human cytomegalovirus (CMV) promoter was prepared
by a series of steps as follows: a 0.7-kb BssHII–SphI frag-
ment of pNL43 (from positions 711 to 1443) was sub-
cloned into pSL1180 (Pharmacia-Biotech, UK) generating
pSLga. A 33-bp deletion in the putative packaging signal,
between the major splice donor and the start site of the
gag gene, was then performed by site directed
mutagenesis with the oligonucleotide 5 ¢ GACGCTCTCGC
ACCCATCTCTCACCAGTCGCCGCCCCTC3 ¢ . Following
verification by sequencing, a further 4.3-kb fragment
SphI–SalI of pNL43 (from positions 1443 to 5785) was
cloned into pSLga generating pSLgagpol. An env gene
containing fragment of pNL43, EcoRI–BamHI (from pos-
itions 5743 to 8465) was cloned into pCi-neo (Promega,
Wallisellen, Switzerland) and a subsequent BglII flanked
fragment (0.5 kb) removed, creating pDenv. A fragment
from the BamHI site in pNL43 (position 8465) to the end
of the nef coding sequence was amplified by PCR and
cloned 3 ¢ of the deleted env gene in pDenv creating
pDenvnef. Finally a single fragment encompassing the
sequence from BssHII to EcoRI of pSLgagpol was cloned
upstream of the deleted env in pDenvnef generating
PCWT (Figure 1a). The packaging constructs pCMVDR8.9
which does not encode Env, Vif, Vpr Vpu or Nef and as
control, the plasmid from which it was derived
pCMVDR8.2 (which like PCWT, encodes all proteins of
HIV-1 except Env) were described previously.10 pMD.G
(schematically represented in Figure 1c) which encodes
the heterologous VSV envelope from the immediate–
early enhancer/promoter of CMV was described pre-
viously.5 Transfer vectors (Figure 1b) were made as fol-
lows: pHR CMV EGFP was produced by removing the
LacZ gene (XbaI–BamHI fragment) from pHR CMV LacZ,5
and replacing it with the gene encoding the enhanced
green fluorescent protein (EGFP) (XhoI–NheI fragment)
from PEGFP-C1 (CLONTECH Laboratories Basel,
Switzerland). PHR pgk EGFP was produced by replacing
the CMV promoter in pHR CMV EGFP with the murine
phosphoglycerate kinase (pgk) promoter.35
Production and assays of vectors
Human embryonic kidney 293T cells36 were maintained
in Dulbecco modified Eagle’s medium supplemented
with 10% foetal calf serum (FCS). For vector production,
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plates and transfected by calcium phosphate DNA pre-
cipitation37 with 26 mg of PCWT, 10 mg of pMD.G and
40 mg of transfer vector. The following morning, cells
were washed and medium replaced, this was repeated
24 h later and 64 h after transfection conditioned medium
was harvested. Preparations of VSV-pseudotyped vectors
were filtered through 0.45 mm filters and concentrated by
ultracentrifugation (50 000 g for 90 min). Titres of vector
preparations were determined by plating HeLa cells at a
density of 1 · 105 cells per 5-cm plate, transducing the
cells with serial dilutions of vector supernatants, fol-
lowed by fluorescence-activated cell sorting (FACS)
analysis 5 days later. Titres ranged from 0.5–5 · 107
IU/ml. Vector supernatants were tested for the presence
of replication competent HIV by innoculation of HTLV
II transformed cells MT-2. Cells were maintained in cul-
ture for 3 weeks to 1 month, samples of culture super-
natant were taken twice weekly and stored at - 20° C. The
p24 level in the supernatant was measured by ELISA
(Abbott). No replication-competent virus was detected.
Supernatant containing GALV pseudotyped MLV,
described in Dardalhon et al23 was a kind gift of V Dard-
alhon and N Taylor (Institute of Molecular Genetics,
Montpellier, France). Infections, using 500 ml of this
supernatant were carried out as for lentiviral vectors.
Isolation and transduction of primary T lymphocytes
Peripheral blood mononuclear (PBMCs) cells from heal-
thy donors were isolated by centrifugation on Ficoll–
Hypaque (density, 1.077 g/ml, Pharmacia) for 30 min
(800 g) at 25° C and washed twice with PBS. The resulting
primary lymphocyte population was grown in RPMI
1640 supplemented with 20% FCS and 1% penicillin-
streptomycin (GIBCO-BRL, Life Technologies, Paisley,
UK). T lymphocytes were activated for 48 h by
phytohemagglutinin A (5 mg/ml) and interleukin-2
(50 U/ml) or immobilised monoclonal antibodies, anti-
CD3 (OKT3) and anti-CD28 (clone-CD28.2; PharMingen;
CD3i/CD28i). For the immobilisation of antibodies, 24-
well non-tissue culture-treated plates (Costar) were
coated with antibody (1 mg/ml in PBS) at 0.5 ml/well for
2 to 4 h at 37° C. The coated plates were then blocked with
1% BSA in PBS for 20 min at 37° C, washed once with
PBS and then used for activation. At day 2 after activation
the cells were harvested and counted. Flow cytometric
analysis indicated that these populations were routinely
up to 90% positive for CD3 and hence highly enriched
for T lymphocytes.
To deplete PBMCs of B cells, monocytes, and CD8+ T
cells, freshly isolated PBMCs were incubated for 1 h at
4° C with Dyna beads (M-450 CD19, M-450 CD14 and M-
450 CD8 respectively: Dynal, Chester, UK). Following
removal of the beads, the remaining cells (80% of which
were CD3+, as assessed by anti-human CD3 antibody (PE,
PharMingen, Becton Dickinson, Oxford, UK) labelling
and FACS analysis) were immediately infected.
Cell transduction and analysis
T cells were transduced with vector as follows unless
otherwise stated: 1 · 106 cells were collected in 15 ml
polypropylene Falcon tubes, resuspended in a given vol-
ume of vector supernatant (25–100 ml) in the presence or
absence of Polybrene (5 mg/ml). Tubes were centrifuged
at 1500 g for 1.5–3 h at room temperature or incubated at
Gene Therapy
room temperature without centrifugation. For transduc-
tion on fibronectin, non-tissue culture treated 24-well
plates (Costar, High Wycombe, UK) were coated with
(20 mg/cm3) or 4 ml polystyrene tubes (Falcon, Fred
Baker, Runcorn, UK) with 400 ml (32 mg/ml) recombinant
fibronectin (fragment CH-296, Takara Schuzo, Otsu,
Shiga, Japan) or with bovine serum albumin (BSA) over-
night at 4 ° C or for 2 h at room temperature. Plates or
tubes were subsequently blocked with 1% BSA (20 min,
37° C) and washed once with PBS before use.
Following transduction, cells were washed once with
PBS and resuspended in medium supplemented with
50 U/ml IL-2. Cells were split or medium changed every
3 days when 50% of the medium was replaced with fresh
medium containing IL-2. On indicated days after trans-
duction, cells were harvested, washed and fixed before
flow cytometric analysis. Fluorescence activated cell
sorting (FACS) was carried out using a FACScan flow
cytometer (Beckton Dickinson) and Lysis II software.
Transduction of cells was detected by the presence of
GFP (488 nm) laser. CD4 and CD8 expression was
assessed by staining with anti-human antibodies labelled
with phycoerythrin (PE, PharMingen, Becton Dickinson).
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